A cure at last? New treatment options for an incurable paediatric leukemia

The drug panel consisted of one hundred drugs, including novel chemotherapeutics that are undergoing clinical development. Striking and specific responses were found for venetoclax (ABT-199), a drug that specifically targets the BCL2 protein, and which has been shown to work in other cancer strains. Follow-up work in mouse models have shown that the drug induces remission when combined with backbone chemotherapy for ALL.
Read More